Capital Q® Ventures Announces Closing of $1 Million Pre-Seed Funding Round for BeeCure® (SanMelix Laboratories)

Investment supports commercialization, market expansion, and continued development of BeeCure®’s specialized skin and wound care solutions.

MAITLAND, FL, UNITED STATES, November 11, 2026 /EINPresswire.com/ — Capital Q^® Ventures Inc., a full-stack venture capital firm, today announced the closing of a $1 million pre-seed funding round for SanMelix Laboratories, Inc., the parent company of BeeCure^®, a developer of specialized skin and wound care products utilizing proprietary buckwheat honey-based formulations.

Capital Q^® Ventures participated as the final investor in the round, completing the $1 million financing and supporting SanMelix Laboratories’ efforts to advance commercialization and its next phase of growth.

Use of Funds and Commercialization Strategy
Proceeds from the financing are expected to support BeeCure^®‘s continued commercialization efforts, with proposed priorities including expanded sales and distribution capabilities, targeted marketing initiatives, product development, and operational resources needed to support growth.

The investment is also intended to strengthen SanMelix’s ability to pursue new commercial opportunities, build strategic relationships, and expand the market reach of its existing and developing product portfolio.

“Successfully closing our $1 million pre-seed round is an important milestone for SanMelix Laboratories and the BeeCure^® brand,” said Steve Weinstein, CEO of BeeCure^®. “With this funding and the continued support of Capital Q^® Ventures, we are focused on advancing our commercialization strategy, expanding our reach, and building on the opportunities ahead.”

As part of its full-stack venture capital model, Capital Q^® Ventures provides portfolio companies with investment capital and significant managerial assistance, supporting business development, strategic planning, and long-term growth initiatives.

“BeeCure^® is addressing a distinct need in specialized skincare with a differentiated product platform,” said Michael “Q” Quatrini, Founder and CEO of Capital Q^® Ventures. “Our investment reflects our confidence in the company’s direction and our commitment to supporting the team as it advances commercialization and expands its market presence.”

With the financing round complete, SanMelix Laboratories will focus on executing its commercial growth strategy and strengthening its position in the specialized skin and wound care market.

About SanMelix Laboratories / BeeCure^®
SanMelix Laboratories, Inc. is a skin and wound care company developing proprietary products featuring buckwheat honey-based formulations. Through its BeeCure^® brand, the company offers specialized skincare solutions, including products formulated to soothe and hydrate skin affected by radiation and laser treatments. SanMelix also maintains a development pipeline focused on advanced wound care applications.

For more information, visit www.beecure.com.

About Capital Q^® Ventures
Capital Q^® Ventures Inc. is a full-stack venture capital firm providing investment capital, significant managerial assistance, and strategic resources to emerging and growth-stage companies. Through its integrated investment and business development model, Capital Q^® Ventures works with portfolio companies to support commercialization, operational development, and long-term growth.

For more information, visit www.capitalqventures.com

Jessica Belvedere
Capital Q Ventures
+1 407-307-2277
jbelvedere@capitalqventures.com

BeeCure® Company Video

Media gallery